Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s ...

MARLBOROUGH, Mass., Jan. 7, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at the 25th North American Neuromodulation Society (NANS) ...

Boston Scientific is taking clear steps to advance its European, Middle East and Africa (EMEA) region market position in the urology space. The company drew significant attention at the J.P. Morgan ...

Boston Scientific is growing its urology portfolio with a $3.7 billion deal to acquire Axonics, makers of neurostimulation therapies for urinary and fecal incontinence. Currently a chief competitor in ...

Medical device maker Boston Scientific said on Monday it had agreed to buy Axonics for $3.7 billion, gaining access to devices used to improve bladder function. The deal marks Boston Scientific's ...

Explore Boston Scientific operations, healthcare technologies, global business presence, product portfolio, and role within ...

Boston Scientific has closed on its $3.7 billion acquisition of Axonics. The Marlborough, MA-based company first announced the deal in January. Axonics develops devices to treat urinary and bowel ...